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Abstract Functional genomics can be defined as the search for
the physiological role of a gene for which only its primary
sequence is known. Most of the genes encoding proteins
containing seven hydrophobic stretches code for G protein-
coupled receptors (GPCRs). Although many of these have been
shown to interact with known natural ligands, several bind
ligands which have not been thus far isolated. These are the so-
called orphan GPCRs. As an example of functional genomics, an
‘orphan receptor strategy’ has been developed to identify the
natural ligands of orphan GPCRs. The application of this
strategy is bound to revolutionize our understanding of the
diversity of the primary messengers which modulate synaptic
transmission. This review discusses the basic concepts and some
of the particular problems associated with the orphan receptor
strategy. The strategy’s potential is exemplified by its successes
which culminated in the discovery of the neuropeptides ‘orphanin
FQ/nociceptin’ and ‘orexins/hypocretins’. The steps that led to
the characterization of these neuropeptides are discussed as are
some of the further studies that have addressed the roles of these
neuropeptides. To conclude, some of the implications of the
application of the orphan receptor strategy are discussed.
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1. The orphan receptor strategy
1.1. The existence of orphan receptors
The hypothesis that transmitter receptors (neurotransmit-
ters, neuropeptides, peptide hormones, eicosanoids, olfactory
receptors) belong to supergene families [1] underlies the belief
that homology screening approaches would lead to the iden-
ti¢cation of novel receptors. These approaches su¡ered from
one obvious problem: how to ¢nd the pharmacological char-
acteristics of the newly cloned receptors? By de¢nition, the
receptors cloned via these strategies would be in search of
their pharmacological identity, their natural ligand. They in-
deed were all ‘orphan’ receptors, i.e. receptors in search of a
function. The pursuit to unravel the identities of orphan re-
ceptors was thought to be a formidable, and to many unre-
solvable, task which would lead to unglamorous ¢shing expe-
ditions (surprisingly, this proved not to be the case for the
¢rst ‘orphan’ G protein-coupled receptor (G-21) [2] which was
soon demonstrated to be the 5-HT1A receptor [3]).
The problem of the pharmacological identity of orphan
receptors became more prominent when approaches speci¢-
cally directed at the identi¢cation of G protein-coupled recep-
tors (GPCRs) by homology screening were developed. The
¢rst one, based on low-stringency hybridization, led to the
cloning of several orphan receptors [4], one of which was
shown to be the dopamine D2 receptor. The second, a
PCR-based approach, also led to the cloning of several or-
phan receptors [5], some of which awaited patient searches to
¢nally ¢nd their pharmacological identity. The application of
these technologies resulted in two major advances.
First, they led to the cloning of most of the pharmacolog-
ically expected receptors and their, sometimes unexpected,
subtypes. To date, cloned GPCRs exist for all the known
neurotransmitters, neuropeptides and peptide hormones
[6,7]. Second, they led to the identi¢cation of receptors which
have kept their orphaned status until this day. These receptors
must bind ligands which have not been thus far characterized,
because inactive receptors should be evolutionarily discarded.
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Fig. 1. Schematic representation of the orphan receptor strategy. A
cell transfected with an orphan GPCR is exposed to a tissue extract
containing the putative natural ligand (top). The ligand receptor in-
teraction induces a second messenger response (large arrow). How-
ever, the complexity of the extract allows for additional molecules
to induce responses (small arrows) making the total response (2nd)
the sum of the orphan GPCR-induced and endogenous responses.
The level of the endogenous responses can be determined in un-
transfected cells (bottom).
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This fact inspired enough con¢dence in a few researchers [8]
to utilize orphan receptors as bait to isolate their natural
ligands, which meant identifying novel transmitters (an ap-
proach reviewed as a ‘neglected opportunity’ [9]).
1.2. The strategy and its pitfalls
The concept that an orphan receptor could be used as bait
to identify a novel transmitter is new in that it implies the
use of a molecular clone but relies on the same path as the
ones which led to the identi¢cation of neuropeptides using
biological assays. The discovery of the opioid peptides [10]
is an example of this. The principle of this concept is to
transfect the cloned orphan receptor into a cell which conse-
quently can be activated by the orphan receptor ligand. By
exposing the transfected cell to a tissue extract containing the
natural ligand of the orphan receptor, a change in intracellu-
lar second messengers will be induced and will serve as a
parameter to monitor the orphan receptor ligand puri¢cation
(Fig. 1).
This concept butts against two unknowns: the physical na-
ture of the ligand and the type of second messenger response
that it will generate. Both of these characteristics are un-
known. GPCRs bind amino acids, biogenic amines, peptides,
proteins, eicosanoids, lipids, odorants and others. There is not
a single technique which will isolate all of these compounds in
bioactive forms. Moreover, GPCRs couple to G proteins to
modulate the activities of adenylyl cyclase, phospholipase C
and A2, channels, phosphodiesterase and possibly other sec-
ond messenger e¡ectors [11]. There are no rules ascertaining
which second messenger will be modulated by an orphan re-
ceptor. Attempting to identify the natural ligand of an orphan
receptor is short of facing a single equation with two un-
knowns (Fig. 2).
There are, however, structural features in orphan GPCRs
which can be used to advantage in evaluating the nature of
their ligands and the second messengers that they will activate.
Analysis of the primary sequence of a GPCR will determine
its relationship to known receptors. A signi¢cant relationship
can help in evaluating the nature of the receptor’s ligand and
its activity. An orphan receptor which is related, even in a low
degree, to a particular receptor family has a higher probability
of sharing a ligand of the same physical nature and a coupling
to similar G proteins. Although there is no certainty that
similar receptors will bind ligands of similar nature and sim-
ilar G protein couplings, it is a fair start for such a search.
The ¢rst obstacle met in identifying the ligand of orphan
receptors is our inability to ensure that an orphan receptor
transfected cell line does indeed express the receptor. North-
ern blot analysis can ascertain that a corresponding mRNA is
expressed but is not a su⁄cient criterion to ensure the expres-
sion of the protein. Expressing tagged receptors could be a
solution but one which opens the possibility that the tag may
interfere with the ligand binding or the receptor coupling. A
simpler, but more demanding, way to overcome this obstacle
is to establish several lines of orphan receptor expressing cells
and to carry them in parallel along the puri¢cation steps.
These lines can be established in di¡erent cellular environ-
ments which further increases the chance of ¢nding the or-
phan receptor induced second messenger system.
The chemical nature of the natural ligand is a major un-
known in orphan receptor research. There exists no single
puri¢cation technique which would allow for the isolation
of all the physically di¡erent orphan receptor ligands. A
choice has to be made from the start. Thus far, ligands of
orphan receptors have been isolated which are peptides or
lipids [12^16]. In every case, the primary sequence of the or-
phan receptor directed the choice of isolation procedure.
Noteworthy, the identi¢cation of novel lipophilic ligands has
thus far relied on testing a battery of synthetic compounds
instead of extracting them from tissue extracts.
The second major unknown in the search for orphan recep-
tor ligands is to ¢nd out which second messenger system the
orphan receptor will induce. Here again, the primary sequence
of the orphan receptor is a revealing feature. GPRCs can
couple to di¡erent second messenger systems in di¡erent cel-
lular environments [17]. It is expected that the G protein con-
tent of a cell is the predominant factor directing which second
messenger systems will be induced by a GPCR. A GPCR
induces at least one ‘obligatory’ second messenger pathway
(its principal pathway) and, in most cases, several ‘accessory’
pathways, which are possibly less e⁄ciently induced but which
will be detectable in arti¢cial environments [17]. If it is impos-
sible a priori to ascertain the ‘obligatory’ induction pathway
of an orphan receptor, one may express it in di¡erent cellular
environments where its ‘accessory’ induction pathway will be
better revealed. One may also modify the G protein content of
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Fig. 2. The inherent dilemma of the orphan receptor strategy. The chemical nature of the orphan receptor ligand and the intracellular responses
that it may induce are unknown. Theoretically, the number of permutations in this equation makes the search for the natural ligand of an or-
phan receptor an impossible task. However, as described in the text, this equation can be resolved.
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a cell to direct an orphan GPCR to a particular pathway.
Furthermore, considering that the vast majority of the
GPCRs modulate partly either adenylyl cyclase activity or
intracellular calcium release, one can expect that any orphan
receptor will a¡ect at least one of these second messenger
systems if tested in a couple of di¡erent cellular environments.
Alternatively, one may monitor the activity of all orphan
GPCRs using GTP-QS binding. Recording G protein induc-
tion via this methodology is seemingly universal, but has not
been applied thus far in orphan GPCR research.
2. Application of the orphan receptor strategy to the isolation
of novel neuropeptides
2.1. Identi¢cation of OFQ/Noc and of OX/Hcrt
The ¢rst deliberate attempt at identifying the ligand of an
orphan receptor took advantage of a particular receptor. A
GPCR had been cloned which exhibited about 65% sequence
identity with the three opioid receptors but which had been
shown not to bind any of the natural or synthetic opioids or
opiates [8,18,19]. Because of its similarities to the opioid re-
ceptors, it was assumed that this receptor might also bind a
peptidergic ligand and share the same coupling mechanism to
second messenger systems as that of the opioid receptors, i.e.
inhibition of adenylyl cyclase activity.
Puri¢cation of the natural ligand of the opioid-like orphan
receptor was achieved simultaneously in two di¡erent labora-
tories starting from either rat or porcine brain extracts [12,13].
Both approaches led to the identi¢cation of a 17 residue long
peptide with the primary structure FGGFTGARKSAR-
KLANQ. This peptide was named orphanin FQ (OFQ) or
nociceptin (Noc). The striking features of OFQ are its simi-
larities to the opioid peptides, most notably its amino-termi-
nal tetrapeptide FGGF reminiscent of the canonical YGGF
of the opioid peptides.
The second attempt at applying the orphan receptor strat-
egy was more general. Over 50 di¡erent cells were established
each expressing di¡erent orphan GPCRs. They were tested for
their abilities to induce intracellular calcium release when sub-
jected to peptide extracts prepared from hypothalami. One
cell line did respond and led to the characterization of two
peptides, the orexins (OXs) which are structurally related and
amidated [15]. These peptides had been previously identi¢ed
to be expressed in the hypothalamus and named hypocretins
(Hcrts) [20].
2.2. Characterization of the orphan receptor ligands
For a ligand to be speci¢c to its receptor, it must bind this
receptor with saturable, displaceable kinetics and with high
a⁄nity. Extracts of organs, especially complex ones such as
brain, contain numerous catabolic products which may bind
to receptors without being speci¢c ligands. OFQ/Noc and OX/
Hcrt were shown to bind and activate their corresponding
orphan receptors with constants in the low nanomolar range
(Kd 0.1 and 20 nM and EC50 1.05 and 30 nM, respectively)
[13,15]. Although the question remains open whether these
peptides are the sole ligands to their respective orphan recep-
tor, these data demonstrated they are natural ligands of the
orphan receptors.
Bioactive peptides are synthesized as part of larger polypep-
tides. Cloning the precursors encoding the newly isolated pep-
tides can not only ascertain their classi¢cation as bioactive but
may also indicate the existence of other co-encoded peptides.
The OFQ/Noc and OX/Hcrt precursors were cloned
[21,22,15]. Both precursors exhibit all the characteristics ex-
pected of a neuropeptide precursor, in particular a signal se-
quence necessary for their secretion and pairs of basic amino
acid residues £anking the peptide sequences which constitute
recognition sites for prohormone convertases. These data
showed that OFQ/Noc and OX/Hcrt can act as bioactive pep-
tides. They further demonstrated that the two OXs/Hcrts are
encoded by a single precursor. In the case of OFQ/Noc, they
raised the possibility that other bioactive peptides may be
generated by the OFQ/Noc precursor [23]. The availability
of the precursor cDNAs allowed for analyses of their site of
synthesis and the demonstration that OFQ/Noc and OXs/
Hcrts are synthesized in the CNS [20,24,25]. This fact sup-
ported their classi¢cation as neuropeptides.
The next step in characterizing orphan receptor ligands is to
search for their physiological roles. Localization of the pep-
tides by immunoreactivity and of precursors and receptors by
in situ hybridization studies is important information toward
this goal. Because of their detection in the lateral hypothal-
amus, OXs/Hcrts were expected to regulate feeding behavior
and energy homeostasis. Indeed, OXs/Hcrts, when injected
intracerebroventricularly (i.c.v.), stimulated food consumption
in a dose-dependent manner [15]. The broad distribution of
the OFQ/Noc system, on the other hand, suggested that it will
regulate many behavioral responses. To date OFQ/Noc has
been implicated in a dozen physiological responses. OFQ/Noc
was ¢rst shown to modulate locomotion and to a¡ect pain
perception. The e¡ects of OFQ/Noc on nociception have been
intensely debated and have been reviewed [18,19]. Originally
OFQ/Noc was reported to have a hyperalgesic activity, an
e¡ect later shown to result from a reversal of stress-induced
analgesia [26]. However, depending on the doses and the route
of administration, OFQ/Noc has also been reported to induce
analgesia [27], and furthermore to induce allodynia in re-
sponse to innocuous tactile stimuli [28]. Because of its simi-
larity to the opioid peptides, OFQ/Noc was tested for its
ability to produce reinforcement behavior [29] and was shown,
in contrast to morphine, not to produce conditioned place
preference or aversion. OFQ/Noc was further shown to pro-
duce an impairment of spatial learning [30], to produce
marked changes in the renal excretion of water and sodium
[31], to exhibit vasorelaxant properties [32], to induce hypo-
tension and cardiac output [33,34] and to a¡ect sexual behav-
iors by facilitating lordosis [35] and penile erection [36]. Sim-
ilar to the Oxs/Hcrts, OFQ/Noc was reported to induce
feeding in satiated rats [37,38]. Finally, OFQ/Noc has been
shown to induce a profound anxiolytic response in mice and
rats [39] in a manner similar to that produced by diazepam.
3. Conclusion: implications of the orphan receptor strategy
Because it permits the identi¢cation of the natural ligand of
a putative receptor known only from its primary sequence, the
orphan receptor strategy stands as an example of a successful
attempt in functional genomics. This strategy, however, makes
us face two questions. The ¢rst relates to the identity of the
isolated ligand. A GPCR can bind di¡erent ligands at di¡er-
ent a⁄nities. The isolated ligand may interact with the recep-
tor without being a truly bioactive molecule. For example,
degradation products of abundant proteins may bind and
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activate a receptor (as was the case of the isolation of OFQ/
Noc [13]). Of course in the case of peptides, the cloning of
their precursors is an important step in overcoming this prob-
lem. But ultimately the possibility that the isolated ligand is
not a bioactive one remains until a physiological response is
shown to be directly modulated by the ligand.
The second question associated with this strategy relates to
the identi¢cation of the central physiological roles of the novel
ligand. Many neurotransmitters and neuropeptides are impli-
cated in numerous behavioral responses, for example, OFQ/
Noc has already shown this tendency. How to de¢ne the
principal role(s) of a novel ligand will be the central aim of
future studies. This underscores the biggest obstacle, and per-
haps the greatest outcome, of orphan receptor research: our
lack of behavioral assays monitoring complex or ‘higher’
brain functions. It is hoped that the description of novel ‘or-
phan’ neuronal systems and their subsequent genetic manipu-
lation (as already begun in the case of the OFQ/Noc system
[40]) will help to develop assays describing novel behavioral
responses. But in the end, it will be the understanding of the
implication of the novel ligand system in the human organism
which will need to be analyzed. This aim unfortunately will be
demanding in time and e¡ort, but the fact that GPCRs are
established as the prominent class of therapeutic targets indi-
cates that orphan GPCRs will be the object of drug discovery
programs.
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